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Introduction {#sec001}
============

Chronic hepatitis C virus (HCV) infection is an inflammatory process of the liver that progressively leads to cirrhosis in about 20--30% of patients \[[@pone.0233212.ref001]\]. The annual risk of hepatocellular carcinoma (HCC) is around 3% in HCV patients with cirrhosis \[[@pone.0233212.ref001]\]. Of all HCV-related HCC, 80--90% occur in the setting of cirrhosis \[[@pone.0233212.ref001]\]. Eradication of HCV has been associated with a decreased risk of developing HCC at any stage of fibrosis \[[@pone.0233212.ref002]\].

The first anti-HCV drugs, predominantly PEGylated interferon-α and ribavirin, can achieve sustained virologic response (SVR) rates in approximately 55% of patients \[[@pone.0233212.ref003]\]. The innovation of direct-acting antiviral (DAA) agents has dramatically improved the SVR rates to more than 95% in all HCV genotypes and shortened the treatment duration \[[@pone.0233212.ref004]\]. In 2013, the FDA approved the second generation of DAAs. A recent study showed that DAA therapy also has a safety profile in decompensated liver disease \[[@pone.0233212.ref004]\]. However, DAA is relatively expensive and, therefore, the cost-effectiveness of treating all HCV individuals, when compared to waiting for treatment until development of a more advanced liver disease or HCC, is controversial. Since January 2017, the DAA was reimbursed by the Taiwan National Health Insurance for HCV patients with advanced hepatic fibrosis or compensated cirrhosis \[[@pone.0233212.ref005]\]. Since 2019, the health insurance covered all HCV-infected patients and pangenotypic regimens were introduced. There was no prohibition or criteria for using DAA in patients with HCC.

In the interferon era, because fewer cirrhosis patients would tolerate longer duration and side effects, the occurrence of HCC has occasionally been observed after the treatment \[[@pone.0233212.ref006]\]. In the age of widening use for DAA, initial studies show that this drug has a high risk of short-term recurrence in patients receiving HCC therapy despite viral eradication \[[@pone.0233212.ref006]--[@pone.0233212.ref008]\]. However, a meta-analysis study shows that there is no evidence that DAA therapy is related to HCC development after adjusting for follow-up period and age \[[@pone.0233212.ref009]\]. The American Gastroenterological Association (AGA) advises that DAA therapy for HCC patients is available to those who receive curative therapy \[[@pone.0233212.ref010]\]. In the clinical scenario, a small proportion of Child--Pugh class B cirrhosis patients without curative HCC treatment received DAA therapy for consideration of its benefit of reverse of liver function and then further HCC treatment. Because the continued risk of recurrent HCC persists in patients receiving DAA therapy after curative therapy, the timing and role of DAA therapy are debatable and inconclusive.

Until now, there are few data on the benefit and outcome of HCV eradication in patients who have already developed HCC. Therefore, we conducted this study with the aim of investigating the impact of treatment with or without DAA among different stages of HCC patients undergoing therapy. The second aim was to evaluate the relationship between DAA therapy and recurrent HCC after curative treatment.

Materials and methods {#sec002}
=====================

Patient selection {#sec003}
-----------------

This was a retrospective study aimed at assessing the outcome of DAA therapy in HCV-related HCC at the MacKay Memorial Hospital, Taipei. The baseline characteristics and laboratory and radiologic tumor patterns were registered in all patients before starting HCC therapy. The inclusion criteria were as follows: (1) patients with HCV infection having a positive HCV viral load test, (2) patients with HCC diagnosed through pathology or noninvasive imaging, and (3) DAA should be prescribed after the diagnosis of HCC. The exclusion criteria were as follows: (1) concomitant HBV or HIV infection, (2) treatment of HCV with interferon, (3) incomplete HCC follow-up, and (4) terminal HCC.

Data collection {#sec004}
---------------

Altogether, between January 2010 and December 2019, 204 consecutive patients with HCV induced HCC under therapy were registered ([Fig 1](#pone.0233212.g001){ref-type="fig"}). Of these, 14 patients with undetectable viral load, and 15 patients with concomitant HBV infection were excluded. During the HCV and HCC treatment, 16 patients with interferon therapy, 15 patients with DAA therapy before HCC diagnosis, 28 patients without complete HCC follow-up, and 9 patients with terminal HCC were not included. Finally, 107 patients were included in this study. Eight patients were diagnosed with HCC before the enrollment period, and the earliest date of diagnosis was December 2004. This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Mackay Memorial Hospital (19MMHIS284e). This was a retrospective observational study, so the need for informed consent was waived by the IRB. The raw and analysis ready datasets were anonymized by removing all personally identifiable information (**[S1 File](#pone.0233212.s001){ref-type="supplementary-material"}**).

![Flowchart of the patients in the study.](pone.0233212.g001){#pone.0233212.g001}

Diagnosis and variable definitions {#sec005}
----------------------------------

HCC was diagnosed with alpha-fetoprotein (AFP) and imaging studies such as ultrasonography, radiocontrast enhanced triphasic dynamic computed tomography (CT), and/or magnetic resonance imaging (MRI) \[[@pone.0233212.ref011]\]. The HCC stage was based on the Barcelona Clinic Liver Cancer (BCLC) staging system and classified into five stages (0, A, B, C, and D) \[[@pone.0233212.ref012]\]. The severity of hepatic fibrosis was assessed by the fibrosis-4 index \[[@pone.0233212.ref013]\]. Liver cirrhosis was evaluated based on the Child--Pugh classification. Cirrhosis was diagnosed by histopathology or by laboratory tests, ultrasonography, and clinical manifestations of patients with chronic hepatitis with portal hypertension and/or hepatic decompensation \[[@pone.0233212.ref014]\]. The albumin-bilirubin (ALBI) grade was calculated to predict the prognosis of HCC \[[@pone.0233212.ref015]\]. The virological response to therapy was assessed by quantitative HCV viral load detection, using real-time polymerase chain reaction with a limit of detection of 15 IU/ml. SVR12 was defined as serum HCV ribonucleic acid levels undetectable 12 weeks after cessation of DAA.

We registered time periods in each patient between HCC diagnosis and therapy, the initiation of DAA, the recurrent HCC after curative therapy, and the last follow-up until December 2019 or HCC-related death. To avoid immortal time bias, all patients who were followed up less than 9 months before DAA therapy were excluded from the analysis. In our hospital, the follow-up policy for HCC patients who achieve complete or partial radiologic response 1 month after therapy is to perform triphasic dynamic imaging. Thereafter, surveillance for HCC consisted of measurements of serum AFP and ultrasonography, CT scan, or MRI scans of the liver every three to six months \[[@pone.0233212.ref011],[@pone.0233212.ref016]\]. Curative therapy was defined as therapy resulting in the disappearance of all target lesions after initial treatment with radiofrequency ablation or hepatectomy. Recurrent HCC was defined as a recently developed nodule with a typical vascular pattern of HCC on dynamic imaging, and its longest diameter is at least 1 cm \[[@pone.0233212.ref017]\].

Statistical analysis {#sec006}
--------------------

Normally and non--normally distributed continuous data were summarized as mean ± standard deviation (SD) and medians with interquartile range (IQR), respectively. Categorical variables were described using frequency distributions and reported as n (%). Student's t-test was used to compare the means of normally distributed continuous variables. The chi-square or Fisher's exact test was used to compare categorical variables. Overall survival (OS) was defined as the interval between the time of HCC diagnosis and death or last follow-up, which was estimated by the Kaplan--Meier method. Recurrence-free survival was defined as the interval between the end of curative therapy and recurrent HCC or last follow-up. The log-rank test was used to determine differences in survival between the groups. Statistical analysis was performed using the STATA statistical package (version 15.0; Stata, College Station, TX, USA). All P values were two-sided, and P\<0.05 was considered statistically significant.

Results {#sec007}
=======

Baseline characteristics of HCV-HCC patients {#sec008}
--------------------------------------------

Among 107 hepatitis C-related HCC patients, 60 patients were treated with DAA after HCC management (DAA group) and 47 patients did not receive any HCV therapy (no DAA group). The baseline characteristics of the study population are reported in [Table 1](#pone.0233212.t001){ref-type="table"}. The age, sex ratio, and laboratory data of complete blood cell count and liver function were comparable between the two groups. The baseline tumor burden, such as the size of the largest tumor, the number of tumors, and AFP were not statistically different. The proportions of the BCLC stage were 0 (4.3%), A (61.7%), B (17%), and C (17%) in the no DAA group and 0 (31.7%), A (48.3%), B (13.3%), and C (6.7%) in the DAA group. More advanced HCC was noted in the no DAA group (P = 0.003). There were no significant differences in the fibrosis-4 index and ALBI grade between the two groups. In the HCC treatment modalities, targeted therapy of sorafenib was commonly prescribed in the no DAA group (P = 0.007), while other therapies did not differ significantly between groups. In total, 24 patients without DAA therapy and 35 patients with DAA therapy received curative HCC therapy.

10.1371/journal.pone.0233212.t001

###### Baseline characteristics of HCV-related HCC patients.

![](pone.0233212.t001){#pone.0233212.t001g}

                                No DAA N = 47     DAA N = 60        P-value
  ----------------------------- ----------------- ----------------- ----------
  Age, years                    67.2 ± 2.7        69.6 ± 2.1        0.913^§^
  Male gender (%)               25 (53.2)         31 (51.7)         0.875^†^
  Body mass index               24.5 ± 1.3        24.9 ± 1.1        0.679^§^
  HCV viral load, log~10~       6.43 ± 6.11       6.36 ± 5.64       0.310^§^
  Albumin, g/dL                 3.5 ± 0.1         3.7 ± 0.1         0.983^§^
  Creatinine, mg/dL             1.03 ± 0.19       0.90 ± 0.40       0.908^§^
  Ascites (%)                   4 (8.5)           4 (6.7)           0.737^†^
  Total bilirubin, mg/dL        1.09 ± 1.05       1.08 ± 0.49       0.542^§^
  ALT, IU/L                     72.0 ± 17.8       72.7 ± 6.9        0.473^§^
  PT-INR                        1.11 ± 0.01       1.12 ± 0.01       0.440^§^
  Sodium, mEq/L                 132.8 ± 4.3       139.2 ± 2.5       0.103^§^
  Hemoglobin, g/dL              12.1 ± 1.7        14.3 ± 1.9        0.152^§^
  White blood cell, 10\^3/uL    5.5 ± 2.3         4.8 ± 1.8         0.958^§^
  Platelet, k/μL                122.8 ± 15.8      116.5 ± 16.4      0.292^§^
  Fibrosis-4 index              6.6 ± 1.5         7.6 ± 1.5         0.167^§^
  Child-Pugh score (A/B)        27 / 12           47 / 8            0.067^†^
  AFP, ng/mL                    2009.8 ± 1564.2   1544.4 ± 1306.9   0.591^§^
  Size of largest tumor (cm)    4.2 ± 3.3         3.0 ± 2.5         0.989^§^
  Tumor no (1/2/3/\>3)          35 / 8 / 1 / 3    48 / 6 / 3/ 3     0.480^†^
  BCLC (0/A/B/C)                2 / 29 / 8 / 8    19 / 29 / 8 / 4   0.003^†^
  ALBI grade (1/2/3)            12 / 31 / 4       17 / 42 / 1       0.249^†^
  **Treatment modality**                                            
      Surgery time              0.4 ± 0.3         0.7 ± 0.5         0.763^†^
      RFA times                 1.2 ± 1.1         1.6 ± 1.5         0.076^†^
      TAE/TACE times            1.2 ± 1.1         1.4 ± 0.9         0.288^†^
      PEIT times                1.7 ± 0.8         1.1 ± 0.6         0.218^†^
      Radiotherapy (%)          4 (7.1)           1 (1.7)           0.096^†^
      Sorafenib (%)             12 (25.5)         4 (6.7)           0.007^†^
      First line- surgery (%)   11 (23.4)         15 (25.0)         0.849^†^
      First line- RFA (%)       15 (31.9)         28 (46.7)         0.112^†^
      Curative therapy (%)      24 (51.1)         35 (58.3)         0.504^†^

Abbreviations: AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine aminotransferase; BCLC,Barcelona clinic liver cancer; HCV, hepatitis C virus; PEIT, percutaneous ethanol injection therapy; PT INR, prothrombin time international normalized ratio; RFA, radiofrequency ablation; TACE, Transarterial chemoembolization; TAE, Transarterial embolization

P value was determined using t-test^§^ or Chi-squared test^†^.

Overall survival in HCC patients with and without DAA therapy {#sec009}
-------------------------------------------------------------

At a median follow-up of 35 months (IQR, 20--56 months), 28% of the patients died. The cumulative incidence of OS at 1, 3, and 5 years was 93.8%, 81.8%, and 61.4%, respectively, in the DAA group and 54.1%, 42.3%, and 24.2%, respectively, in the no DAA group. Patients who received DAA therapy had a significantly longer OS than patients without DAA therapy (P\<0.001) ([Fig 2A](#pone.0233212.g002){ref-type="fig"}). When stratified by BCLC staging, there was a statistical difference in survival among patients undergoing DAA therapy for the early stage (BCLC stage 0-A) (1-year OS 94.4% vs. 79.6%; 3-year OS, 84.5% vs. 61.9%; P = 0.034) ([Fig 2B](#pone.0233212.g002){ref-type="fig"}). In BCLC stage B-C, the DAA group had a significantly higher OS rate than the no DAA group (1-year OS, 91.3% vs. 67.7%; 3-year OS, 65.2% vs. 26.1%; P = 0.006) ([Fig 2C](#pone.0233212.g002){ref-type="fig"}).

![Overall survival of HCC patients with and without DAA therapy.\
Patients with DAA therapy (A), BCLC stage 0-A (B), and BCLC stage B-C (C) had significantly higher overall survival rates than their counterparts.](pone.0233212.g002){#pone.0233212.g002}

Characteristics of patients receiving DAA {#sec010}
-----------------------------------------

Among the 60 patients receiving DAA therapy, the most common genotype was genotype 1b (60.0%), followed by genotype 2 (36.7%) ([Table 2](#pone.0233212.t002){ref-type="table"}). Harvoni was the most commonly used DAA regimen in 35% of patients, followed by Sovaldi (16.6%), Zepatier (13.3), and Viekirax + dasabuvir (13.3%). The rapid viral response and SVR12 were 88.3% and 93.3%, respectively. Thirty-five patients (58.3%) received DAA after curative HCC therapy. The median period from curative HCC therapy to DAA prescription was 24 months (IQR, 15--48 months). There were four patients who failed DAA treatment. Among them, three patients (75%) belonged to genotype 2, and three patients (75%) only had a partial response to HCC therapy before DAA use. In all, 13 (37.1%) patients had recurrent HCC after curative therapy, and the median follow-up period was 20 months (IQR, 11--26 months).

10.1371/journal.pone.0233212.t002

###### Characteristics of the HCC patients who received DAA therapy.

![](pone.0233212.t002){#pone.0233212.t002g}

                                                    N = 60   \% or IQR
  ------------------------------------------------- -------- -----------
  **Genotype of HCV**                                        
      1a                                            2        3.3
      1b                                            36       60.0
      2                                             22       36.7
  **DAA agent**                                              
      Harvoni                                       21       35.0
      Sovaldi                                       10       16.6
      Zepatier                                      8        13.3
      Viekirax + exviera                            8        13.3
      Sofosbuvir-based                              6        10.0
      Maviret                                       4        6.7
      Daklinza+ sunvepra                            3        5.0
  **Rapid viral response**                          53       88.3
  **12-week sustained viral response**              56       93.3
  **DAA therapy after HCC diagnosis (months)**      25       17--42
  **DAA therapy after curative therapy (months)**   24       15--48
  **Curative therapy (N = 35)**                              
      Recurrent HCC                                 13       37.1
      Follow-up period after DAA therapy (months)   20       11--26

Recurrent HCC after curative treatment {#sec011}
--------------------------------------

Among the 59 HCC patients who received curative therapy, 24 patients (40.7%) had HCC recurrence after the median follow-up time of 21 months (IQR, 12--32 months). The recurrence rates were 37.1% and 45.8% in the DAA and no DAA groups. The cumulative incidences of recurrence-free survival at 1, 2 and 3 years were 85.1%, 73.2% and 40.7%, respectively, in the DAA group and 82.9%, 78.2% and 60.9%, respectively, in the no DAA group. There was no statistically significant difference in the recurrence rate among patients receiving or not receiving DAA (P = 0.278) ([Fig 3](#pone.0233212.g003){ref-type="fig"}).

![Recurrence-free survival in HCC patients with and without DAA therapy.](pone.0233212.g003){#pone.0233212.g003}

Discussion {#sec012}
==========

With a higher rate of HCC in patients with HCV than in patients with other causes of cirrhosis \[[@pone.0233212.ref018]\], realizing the impact of DAA therapy on long-term outcomes in this population is vital. It is likely that there is improved median OS seen in our cohort among patients under HCC treatment receiving DAA therapy. After curative HCC therapy, application of the DAA does not increase or reduce the risk of HCC recurrence in our analysis.

In the pathogenesis of HCV-related HCC, it remains controversial whether the virus plays a direct or indirect role. The core protein of HCV has an oncogenic potential in transgenic mouse models, indicating that HCV is directly involved in hepatocarcinogenesis \[[@pone.0233212.ref019]\]. In the indirect pathway, HCV causes HCC via chronic inflammation, proliferation, and cirrhosis \[[@pone.0233212.ref020]\]. The presence of cirrhosis played an important risk factor for developing HCC among HCV patients \[[@pone.0233212.ref018]\]. HCV genotype 1b--related cirrhosis carry a significantly higher risk of developing HCC than other genotypes \[[@pone.0233212.ref021], [@pone.0233212.ref022]\]. In Taiwan, the Type 1b virus is the predominant genotype of HCV \[[@pone.0233212.ref022]\], and it was also a major cause of HCC in patients receiving DAA therapy in our study.

There are two factors that determine HCC development \[[@pone.0233212.ref023]\]. The risk of HCC likely decreases after viral clearance, but the patient's age increases the risk of HCC \[[@pone.0233212.ref023]\]. Furthermore, patients with a history of HCC present a high risk of recurrent HCC. A large study in Asia showed that the overall occurrence rate of HCC after DAA treatment in patients with previous HCC history was 29.6% and only 1.3% in patients without previous HCC history \[[@pone.0233212.ref006]\]. The HCC recurrence rate after DAA therapy was higher in this study (37.1%), which may be related to the longer follow-up duration (20 months vs. 15 months) \[[@pone.0233212.ref006]\]. Due to the risk of HCC recurrence, surveillance at 4-month intervals after DAA therapy in patients with HCC history was recommended \[[@pone.0233212.ref006]\].

Most patients with HCC are frequently challenged by impaired liver function as a result of cirrhosis, apart from the HCC burden. All guidelines recommend that preserved liver function is a vital prerequisite to deliver effective HCC treatment \[[@pone.0233212.ref024], [@pone.0233212.ref025]\]. After HCV eradication, liver fibrosis could significantly improve in the long term \[[@pone.0233212.ref026]\]. One study showed that DAA improves decompensated cirrhosis, which reduces waiting list registrations for liver transplantation \[[@pone.0233212.ref027]\]. Further, a study proposed a predictive score to evaluate the potential benefits of DAA therapy in decompensated cirrhosis \[[@pone.0233212.ref028]\]. They found that five baseline factors of body mass index, encephalopathy, ascites, and serum levels of alanine aminotransferase and albumin were related to a reduction of the Child--Pugh score to class A \[[@pone.0233212.ref028]\]. Therefore, the DAA improved the outcome of HCC, which may relate to the improvement or preservation of liver function. Patients could receive further therapies for the progression or recurrence of HCC after HCV eradication. To consider the risk of liver failure and tumor burden in the terminal stage of HCC, DAA was not prescribed in our general practice; therefore, this stage was excluded. A previous study revealed that the OS in stage D patients was worse in patients adherent to HCC therapy than in nonadherent patients \[[@pone.0233212.ref029]\]. AASLD guidance recommends that patients with a life expectancy of less than 12 months are unlikely to benefit from HCV eradication and therefore palliative care is suggested \[[@pone.0233212.ref030]\].

The treatment of HCV-related HCC is controversial since the first published paper showed that recurrent HCC occurred after DAA therapy \[[@pone.0233212.ref031]\]. However, this study was limited by an increased risk of HCC for patients who did not undergo HCV treatment in comparison to the expected annual risk for patients treated with DAAs. In a large French study and an American cohort study, there does not seem to be an association between curing HCV with DAA agents and an increased risk of HCC recurrence \[[@pone.0233212.ref032]\]. A review study showed that several risk factors may increase the risk of HCC recurrence after DAA treatment, such as liver cirrhosis, antiviral treatment failure, history of previous HCC recurrence, initial HCC stage, non-curative HCC therapy, and the time interval of DAA initiation \[[@pone.0233212.ref033]\]. Our study confirmed that there is no evidence for an association between DAA therapy and a higher risk of recurrent HCC after curative therapy. Current experts suggest that it is important to confirm the absence of the tumor prior to starting DAA therapy \[[@pone.0233212.ref023]\].

Decisions regarding DAA treatment in HCC patients should be considered in light of the tumor stage, liver function, life expectancy, and patient preferences. The optimal timing of HCV treatment in patients with HCC is debatable. Patients who have undergone potentially curative HCC management would not benefit from delayed DAA therapy \[[@pone.0233212.ref009]\]. The AGA advises that the best timing for DAA therapy is 4--6 months after a complete response to HCC therapy \[[@pone.0233212.ref010]\]. The variable timing of DAA therapy among HCC patients is noted in this real-world study, and only 58.3% DAA prescription after curative HCC therapy meets the guidelines. In Taiwan, physicians start DAA therapy more quickly after the broadening of the reimbursement criteria and recent studies have shown less evidence of recurrent HCC after DAA therapy \[[@pone.0233212.ref009]\]. With the sequential application of the available systemic treatment options, especially immunotherapy, an OS of more than two years is feasible for patients with advanced stage HCC \[[@pone.0233212.ref034]\]. Repetitive locoregional therapies and chronic hepatitis C may affect liver function in the long term. Timing to switch to systemic therapy and HCV eradication to preserve liver function would prolong post-progression survival and improve OS of patients with HCC patients \[[@pone.0233212.ref034],[@pone.0233212.ref035]\]. Therefore, individualized DAA treatment among HCV patients in different stages of HCC will enhance the outcome and likely become a future trend.

Limitations {#sec013}
-----------

First, this study was a small, single-center, retrospective design, which might have led to patient selection bias. Few advanced HCC patients underwent DAA therapy since the role of DAA is uncertain, and the possibility of curative therapy is low, resulting in little evidence about the benefits of DAA therapy in the late stages of HCC. Second, most patients undergo HCV eradication in the era of DAA, which would result in different treatment periods in HCC patients with and without DAA therapy. Third, the timing of DAA therapy may be delayed in some HCC patients due to the different reimbursement criteria, timing of pangenotypic DAA agent introduction, and physician attitude. Large, prospective cohorts with adequately homogeneous patient populations, in terms of HCC staging system, treatment strategy, and evaluation of HCC response after DAA administration, are needed.

Conclusions {#sec014}
===========

DAA therapy has a survival benefit in patients with HCC. After curative HCC therapy, there is no association between DAA therapy and recurrent HCC.

Supporting information {#sec015}
======================

###### Raw data.

(XLSX)
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Click here for additional data file.
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1\. In this study, the mean duration from HCC diagnosis to the initiation of DAA therapy was 8.9 months. Moreover, the mean duration from curative HCC therapy to DAA prescription was 11.5 months. It might cause an immortal time bias between patients with and those without DAA therapy after the diagnosis of HCC. There might be two methods to minimize this imbalanced bias. The first one is to perform the date of DAA initiation as a time-dependent covariate. For patients in the DAA group, they were classified as the DAA untreated group before the prescription of DAA (untreated period). They were enrolled as DAA treated group after they received DAA therapy (treated period, from DAA initiation to end of follow-up). The second one is to set a time window. All patients started to be followed up after the index date (maybe 9 months or 1 year after the date of HCC diagnosis). All events occurred before the index date were excluded from the analysis.

2\. From the "data collection" in the section of "Materials and methods", patients were enrolled from January 2010 to December 2019. Moreover, the last follow-up date was December 2019. It seemed that the longest follow-up period was 10 years (120 months). However, in the section of "Results", the range of follow-up was 1-180 months. Moreover, in the Figure 2A, at least 7 patients (4 in the non-DAA group, and 3 in the DAA group, respectively) had a follow-up duration of 132 months or more. Please clarify it.

3\. In the Table 2, among the all 60 patients in the DAA group, 35 patients received HCC curative therapy. However, in the Page 11, Paragraph 2 (recurrent HCC after curative treatment), in the early stage (BCLC stage 0-A) of HCC patients receiving curative therapy, 48 patients received DAA therapy. Please to clarify it.

4\. In this study, TACE was regarded as a curative treatment. However, the overall survival rate and tumor control rate were lower in patients who underwent TACE when compared to resection surgery or local ablation therapy. It is suggested to classified TACE as the non-curative treatment modality. Moreover, in the Table 1, it is suggested to show the data of patient number according to their first treatment modality for HCC (for example, how many patients underwent resection surgery at the time of HCC diagnosis between DAA and non-DAA groups).

5\. It is suggested to provide the data of FIB-4 and albumin-bilirubin (ALBI) grade in the Table 1.

6\. It is suggested to provide the median and IQR when presenting the data regarding the follow-up period.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1:

1\. Since the patients who treated with interferon (IFN)-based regimen were excluded in the enrollment per the study design, please correct the following sentence on page 11: "...30 patients received non-DAA therapy (did not receive DAA therapy?)...".

Answer 1: Thanks for your comment. We corrected this error. After refining the criteria for curative therapy (initial treatment with surgery or RFA), 24 patients received non-DAA therapy.

2\. Please make sure that HCV-related HCC BCLC stage 0-A patients who did not receive DAA therapy are 30 instead of 31 as that labeled in Figure 2B.

Answer 2: Thanks for your comment. There were 31 patients (2 and 29 patients in stage 0 and stage A, respectively) in the non-DAA therapy group, and 30 of them received curative therapy in the initial analysis.

3\. Given the high HCC recurrence rate after curative therapy in this study compared with that reported in reference 6, the authors need to explain the possible mechanisms associated with HCC recurrence.

Answer 3: The recurrence of HCC after DAA therapy was higher in this study at 50% (30/60) than in reference 6 (29.6%), since we included patients who showed complete HCC response to TACE therapy and repeated surgery or RFA. After excluding these patients, the recurrence rate in the DAA therapy group was 37.1% (13/35). The follow-up time was longer in this study than in reference 6 (20 months vs. 15 months), which might be another reason. We mentioned this in the discussion.

4\. Small case number especially patients in BCLC intermediate or advanced stages is the main shortcoming for this study.

Answer 4: Thanks for your comment. Because of the small number of HCC patients in advanced stages, this study cannot provide solid evidence of the benefit of DAA in these stages. We mentioned this as the main shortcoming in the discussion.

Reviewer \#2:

1\. In this study, the mean duration from HCC diagnosis to the initiation of DAA therapy was 8.9 months. Moreover, the mean duration from curative HCC therapy to DAA prescription was 11.5 months. It might cause an immortal time bias between patients with and those without DAA therapy after the diagnosis of HCC. There might be two methods to minimize this imbalanced bias. The first one is to perform the date of DAA initiation as a time-dependent covariate. For patients in the DAA group, they were classified as the DAA untreated group before the prescription of DAA (untreated period). They were enrolled as DAA treated group after they received DAA therapy (treated period, from DAA initiation to end of follow-up). The second one is to set a time window. All patients started to be followed up after the index date (maybe 9 months or 1 year after the date of HCC diagnosis). All events occurred before the index date were excluded from the analysis.

Answer 1: Thanks for your precious comment. We chose the second method to exclude immortal time bias. After adjustment, the median periods of HCC diagnosis to DAA therapy and curative HCC therapy to DAA prescription were 25 and 24 months, respectively. We revised this in the methods, tables, and results.

2\. From the "data collection" in the section of "Materials and methods", patients were enrolled from January 2010 to December 2019. Moreover, the last follow-up date was December 2019. It seemed that the longest follow-up period was 10 years (120 months). However, in the section of "Results", the range of follow-up was 1-180 months. Moreover, in the Figure 2A, at least 7 patients (4 in the non-DAA group, and 3 in the DAA group, respectively) had a follow-up duration of 132 months or more. Please clarify it.

Answer 2: Thanks for your comment. Eight patients (5 in the non-DAA group, and 3 in the DAA group) received HCC diagnosis before 2010 and received therapy during the study period of 2010--2019. The earliest date of diagnosis was December 2004. We mentioned this in the methods.

3\. In the Table 2, among the all 60 patients in the DAA group, 35 patients received HCC curative therapy. However, in the Page 11, Paragraph 2 (recurrent HCC after curative treatment), in the early stage (BCLC stage 0-A) of HCC patients receiving curative therapy, 48 patients received DAA therapy. Please to clarify it.

Answer 3: Thanks for your comment. Thirteen patients who showed complete response to HCC after TACE or repeated therapy were included. We revised this in the results.

4\. In this study, TACE was regarded as a curative treatment. However, the overall survival rate and tumor control rate were lower in patients who underwent TACE when compared to resection surgery or local ablation therapy. It is suggested to classified TACE as the non-curative treatment modality. Moreover, in the Table 1, it is suggested to show the data of patient number according to their first treatment modality for HCC (for example, how many patients underwent resection surgery at the time of HCC diagnosis between DAA and non-DAA groups).

Answer 4: Thanks for your comment. We excluded patients who received TACE therapy as a curative treatment and re-analyzed the data as suggested. We have provided the data on initial treatment modality in Table 1.

5\. It is suggested to provide the data of FIB-4 and albumin-bilirubin (ALBI) grade in the Table 1.

Answer 5: Thanks for your comment. FIB-4 and albumin-bilirubin grade were vital tools to evaluate liver fibrosis and HCC prognosis. We added these data in the table.

6\. It is suggested to provide the median and IQR when presenting the data regarding the follow-up period

Answer 6: Thanks for your comment. We revised all data on the follow-up periods by providing the median and IQR.
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Dear Dr. Chen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 11 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Chen-Hua Liu

Academic Editor
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1. The authors had revised my previous comments point-by-point in its 2nd version.

2\. The term "non-DAA therapy" is easily interpreted as "any kinds of antiviral therapies other than DAA" by the readers, I suggest the authors adjust the statement appropriately and consistently in the context.

3\. Polish the language by a native English speaker and give the approval certificate to the editorial office.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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1.The authors had revised my previous comments point-by-point in its 2nd version.

Answer 1: Thanks for your comment.

2\. The term "non-DAA therapy" is easily interpreted as "any kinds of antiviral therapies other than DAA" by the readers, I suggest the authors adjust the statement appropriately and consistently in the context.

Answer 2: Thanks for your comment. We have replaced the term "non-DAA therapy" to "no DAA group" and refined the definition of this group in the results section.

3\. Polish the language by a native English speaker and give the approval certificate to the editorial office.

Answer 3: We have sent the manuscript to an English language editor and provided the associated certificate to the editorial office, as suggested.
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Dear Dr. Chen,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Dear Dr. Chen:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.
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